Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Kura Oncology, Inc.NASDAQ: KURA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$73.33M, compared with -$57.43M a year earlier. Trailing-twelve-month net income was -$294.57M.
Context
- Net income amounted to 412.9% of revenue in FY2025, up 90.1 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$287.81M (-3.3%) for the fiscal year ending Dec 2026, a step up from the -60.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$73.33M+9.5% QoQ
- Last fiscal yearDec 2025
- -$278.67M-60.2% YoY
- LTMMar 2026
- -$294.57M-62.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.7% | -19.2% | +8.5 pp |
| 1 year | -60.2% | -3.3% | +56.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (278.67M) USD
- Year-over-year change
- -60.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (278.67M) | -60.2% |
| FY2024 | 2024-12-31 | (173.98M) | -14.0% |
| FY2023 | 2023-12-31 | (152.63M) | -12.4% |
| FY2022 | 2022-12-31 | (135.84M) | -4.1% |
| FY2021 | 2021-12-31 | (130.47M) | — |
Net Income vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 net income of -$294.57M is the lowest of the 11 companies compared; the peer median is -$87.93M.
- Its year-over-year change of -62.0% is the 10th highest of 11, against a peer median of +3.3%.
- Net income amounts to 411.2% of revenue for KURA, versus a peer median of 116.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $466.88M | +1212.4% | — | 77.5% | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Aug 2026 | $294.88M | +220.5% | — | 42.0% | |
| LTM Sep 2026 | -$35.76M | -37.8% | — | — | |
| LTM Mar 2026 | -$44.76M | +8.4% | — | 8526.1% | |
| LTM Mar 2026 | -$131.11M | -36.0% | — | — | |
| LTM Mar 2026 | -$135.21M | -1.8% | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | -$154.1M | -90.5% | — | — |
| LTM Mar 2026 | -$193.96M | -30.3% | — | 391.2% | |
| LTM Mar 2026 | -$243.25M | +26.6% | — | 112.0% | |
| LTM Mar 2026 | -$294.57M | -62.0% | — | 411.2% | |
| Peer median (excluding KURA) | -$87.93M | +3.3% | — | 116.8% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| Weighted Avg Shares | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Weighted Avg Shares (Diluted) | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.